Federal Register #2026-07907

Executive Order to Accelerate Medical Treatments for Serious Mental Illness

This executive order from the Executive Office of the President outlines a federal initiative to accelerate medical treatments for serious mental illness, with a focus on psychedelic drugs. - Government Buyers: - Executive Office of the President - Food and Drug Administration (FDA) - Department of Health and Human Services (HHS) - Department of Veterans Affairs - Drug Enforcement Administration (DEA) - Attorney General - Products/Services Requested: - No specific products, OEMs, or vendors are named - The order directs prioritization of psychedelic drugs (including ibogaine compounds) with Breakthrough Therapy designation - Funding of at least $50 million to support state programs advancing psychedelic drug treatments - Unique/Notable Requirements: - FDA to prioritize review and facilitate patient access to psychedelic drugs under the Right to Try Act - DEA to provide necessary Schedule I handling authorizations - HHS to allocate funding through the Advanced Research Projects Agency for Health - Mandated collaboration among HHS, FDA, VA, and the private sector to increase clinical trial participation and data sharing - Attorney General to expedite review and potential rescheduling of approved Schedule I substances for mental health treatment - No procurement of specific products or services is announced; this is a policy and funding directive, not a solicitation.

Description

This presidential document issued by the Executive Office of the President focuses on accelerating medical treatments for serious mental illness. It outlines policies to prioritize FDA review of psychedelic drugs with Breakthrough Therapy designation and facilitate patient access under the Right to Try Act. The order directs funding to support state programs advancing psychedelic drug treatments and promotes collaboration among federal agencies and the private sector to increase clinical trial participation and data sharing. It also calls for timely rescheduling of approved Schedule I substances for mental health treatment.

View original listing